Larimar Therapeutics Investor Relations Material

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on its lead compound, CTI-1601, which is currently being developed as a potential treatment for Friedreich's ataxia, a genetic disorder that affects the nervous system and movement. Larimar leverages its proprietary intracellular delivery platform to design fusion proteins aimed at addressing other rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania, and its shares are listed on the Nasdaq.